Prawo i regulacje · 22/02/2007

DEA Proposes Lisdexamfetamine Scheduling in Schedule II

The Drug Enforcement Administration (DEA) is proposing to place lisdexamfetamine, including its salts and isomers, into Schedule II of the Controlled Substances Act (CSA), pending approval of a New Drug Application (NDA) for a lisdexamfetamine product by the FDA.